Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.22% |
| Dec 31, 2025 | -0.48% |
| Sep 30, 2025 | 9.63% |
| Jun 30, 2025 | -3.66% |
| Mar 31, 2025 | -28.72% |
| Dec 31, 2024 | -29.31% |
| Sep 30, 2024 | -38.47% |
| Jun 30, 2024 | -39.29% |
| Mar 31, 2024 | -56.37% |
| Dec 31, 2023 | -26.69% |
| Sep 30, 2023 | -24.76% |
| Jun 30, 2023 | -31.40% |
| Mar 31, 2023 | -37.61% |
| Dec 31, 2022 | -34.22% |
| Sep 30, 2022 | -21.82% |
| Jun 30, 2022 | -28.31% |
| Mar 31, 2022 | -42.23% |
| Dec 31, 2021 | -41.60% |
| Sep 30, 2021 | -68.43% |
| Jun 30, 2021 | -81.75% |
| Mar 31, 2021 | -64.68% |
| Dec 31, 2020 | -18.12% |
| Sep 30, 2020 | -47.72% |
| Jun 30, 2020 | -49.47% |
| Mar 31, 2020 | -17.09% |
| Dec 31, 2019 | -21.50% |
| Sep 30, 2019 | 29.41% |
| Jun 30, 2019 | -33.87% |
| Mar 31, 2019 | 22.10% |
| Dec 31, 2018 | 43.88% |
| Sep 30, 2018 | 48.41% |
| Jun 30, 2018 | 44.12% |
| Mar 31, 2018 | 17.79% |
| Dec 31, 2017 | -16.46% |
| Sep 30, 2017 | 19.03% |
| Jun 30, 2017 | 36.64% |
| Mar 31, 2017 | -16.32% |